Antipsychotics as antidepressants
- 12 May 2015
- journal article
- review article
- Published by Wiley in Asia-Pacific Psychiatry
- Vol. 8 (3) , 179-188
Abstract
Three second‐generation antipsychotic (SGA) agents have receivedFDAapproval for adjunctive treatment, to antidepressant, of major depressive disorder: quetiapine, aripiprazole, and olanzapine. Additionally, quetiapine and lurasidone have been approved for the treatment of bipolar depression. There are data suggesting that quetiapine is effective for major depressive disorder as monotherapy. These agents are effective for depression only at subantipsychotic doses. Receptor profiles predict that allSGAwill have anxiolytic effects as subantipsychotic doses but that all will be dysphorogenic at full antipsychotic doses (i.e., produce a depression‐like clinical picture). The antidepressant effect appears to be unique to some agents, with direct evidence of insignificant antidepressant action for ziprasidone. Three general principles can guide the use of antipsychotics as antidepressants: (i) AllSGAsmay have anxiolytic effects; (ii) full antipsychotic doses are dysphorogenic, and therefore, subantipsychotic doses are to be used; and (iii)SGAsdo not have a general antidepressant effect, rather, this appears to be unique to quetiapine and aripiprazole, and possibly lurasidone.Keywords
Funding Information
- Merck
- Teva
- AssureRx
This publication has 72 references indexed in Scilit:
- Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trialsBMC Psychiatry, 2012
- EXTENDED RELEASE QUETIAPINE FUMARATE IN MAJOR DEPRESSIVE DISORDER: ANALYSIS IN PATIENTS WITH ANXIOUS DEPRESSIONDepression and Anxiety, 2012
- QuetiapineCNS Drugs, 2012
- Selective serotonin 5-HT2C receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cuesNeuropharmacology, 2011
- Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trialsBMC Psychiatry, 2011
- Treating Generalized Anxiety Disorder With Second Generation AntipsychoticsJournal of Clinical Psychopharmacology, 2011
- Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant StrategyNeuropsychopharmacology, 2011
- The 5-HT7 receptor as a mediator and modulator of antidepressant-like behaviorBehavioural Brain Research, 2010
- Quetiapine Monotherapy as Treatment for Anxiety Symptoms in Patients With Bipolar DepressionThe Primary Care Companion For CNS Disorders, 2009
- A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depressionJournal of Psychiatric Research, 2009